News
Press Release
RepliCel Terminates License Agreement with Shiseido
3 years ago
Dec 21, 2021 VANCOUVER, BC, CANADA – 21 December 2021 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2)...
.jpg?width=375&height=210&mode=max)
Press Release
RepliCel Closed Final Tranche of Strategic Investment Commitment
3 years ago
Dec 21, 2021 VANCOUVER, BC, CANADA – 21 December 2021 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel”...
Press Release
RepliCel Ships DermaPreciseTM Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
3 years ago
Nov 11, 2021 Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection...
Press Release,Product - RCI-02
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
3 years ago
Nov 09, 2021 RepliCel’s CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearanceVANCOUVER, BC,...
Press Release
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
3 years ago
Oct 28, 2021 Trademark registrations kickoff pre-commercial planningVANCOUVER, BC, CANADA – 28 October 2021 – RepliCel Life Sciences...
.jpg?width=375&height=210&mode=max){kind=spacer}
Press Release,Product - RCI-02
RepliCel Announces Dermal Injector Update
3 years ago
Oct 27, 2021 Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality...
Press Release
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
3 years ago
Oct 18, 2021 After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking...
Press Release
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
3 years ago
Oct 12, 2021 Kunihiko Suzuki, one of the leading pioneers in Japan’s emerging regenerative medicine industry, commits to...
Press Release
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
3 years ago
Sep 16, 2021 Canadian granting agency MITACS commits to three years of funding for the project’s second stage...
Press Release
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
3 years ago
Jul 07, 2021 Clinical development of RepliCel’s skin rejuvenation and tendon regeneration injectables continues to meet milestones on...
Press Release
RepliCel Adds Independent Director
3 years ago
Jun 15, 2021 Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC – June...
Press Release
RepliCel Launches Testing of Dermal Injector Units
4 years ago
May 25, 2021 Initial units delivered and first phase of functional testing nearly completeVANCOUVER, BC, CANADA – 25...
Press Release
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
4 years ago
May 19, 2021 Clinical research organization, Accerise Inc., has been retained to work with RepliCel and its other...
Press Release
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
4 years ago
May 17, 2021 Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel’s Skin Rejuvenation...
Press Release
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
4 years ago
May 11, 2021 Early identification of unique cell markers is expected to have valuable impact on patents, clinical...
Press Release
RepliCel Announces Record Year in Patents Granted
4 years ago
May 05, 2021 Patents granted in the United States, China, South Korea, Japan, Israel and New Zealand for...
Press Release
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
4 years ago
May 03, 2021 Professor Tsukasa Kumai, member of the Japan’s Olympic Committee Medical and Scientific Staff, will lead...
Press Release
RepliCel Closes Second Tranche of Strategic Investment Commitment
4 years ago
Apr 29, 2021 MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment AgreementVANCOUVER, BC, CANADA – 29 April...
Events
RepliCel Presents its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference
4 years ago
Feb 18, 2021 Kanagawa Regeneration and Cell Medical Industry Network Organizers Invite RepliCel to Participate in Foreign Company...
Press Release
RepliCel Closes First Tranche of Strategic Investment Commitment
4 years ago
Feb 10, 2021 MainPointe Pharmaceuticals Completes Initial Share Purchase per Investment AgreementVANCOUVER, BC, CANADA – 10 February 2021...
by Topic
DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.